HK1206627A1 - Compositions and methods for inhibiting viral polymerase - Google Patents

Compositions and methods for inhibiting viral polymerase

Info

Publication number
HK1206627A1
HK1206627A1 HK15107309.4A HK15107309A HK1206627A1 HK 1206627 A1 HK1206627 A1 HK 1206627A1 HK 15107309 A HK15107309 A HK 15107309A HK 1206627 A1 HK1206627 A1 HK 1206627A1
Authority
HK
Hong Kong
Prior art keywords
compositions
methods
viral polymerase
inhibiting viral
inhibiting
Prior art date
Application number
HK15107309.4A
Other languages
English (en)
Chinese (zh)
Inventor
Pravin L Kotian
Yarlagadda S Babu
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of HK1206627A1 publication Critical patent/HK1206627A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK15107309.4A 2012-04-18 2015-07-30 Compositions and methods for inhibiting viral polymerase HK1206627A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261625994P 2012-04-18 2012-04-18
PCT/US2013/036945 WO2013158746A1 (fr) 2012-04-18 2013-04-17 Compositions et procédés d'inhibition d'une polymérase virale

Publications (1)

Publication Number Publication Date
HK1206627A1 true HK1206627A1 (en) 2016-01-15

Family

ID=49384030

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15107309.4A HK1206627A1 (en) 2012-04-18 2015-07-30 Compositions and methods for inhibiting viral polymerase

Country Status (15)

Country Link
US (2) US9580428B2 (fr)
EP (1) EP2838535B1 (fr)
JP (2) JP2015514772A (fr)
KR (3) KR102409853B1 (fr)
CN (1) CN104379146B (fr)
AR (1) AR090699A1 (fr)
AU (1) AU2013249344B2 (fr)
BR (1) BR112014025909B1 (fr)
CA (1) CA2870722C (fr)
HK (1) HK1206627A1 (fr)
IL (1) IL235123A (fr)
MX (1) MX363270B (fr)
RU (1) RU2654482C2 (fr)
TW (1) TWI664180B (fr)
WO (1) WO2013158746A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5902698B2 (ja) 2010-10-15 2016-04-13 バイオクライスト ファーマシューティカルズ， インコーポレイテッド ポリメラーゼの阻害のための方法および組成物
US20150291596A1 (en) * 2012-11-16 2015-10-15 Biocryst Pharmaceuticals, Inc. Antiviral azasugar-containing nucleosides
CN103864791B (zh) * 2014-03-18 2016-01-27 福建天泉药业股份有限公司 一种恩替卡韦衍生物及其制备方法
CN104513249B (zh) * 2014-12-26 2016-08-31 苏州明锐医药科技有限公司 抗埃博拉病毒药物bcx4430的制备方法
JP2018502858A (ja) * 2015-01-07 2018-02-01 ユーロ−セルティック エス． ア． フォロデシンの製造方法
WO2021207386A1 (fr) * 2020-04-07 2021-10-14 Biocryst Pharmaceuticals, Inc. Procédés, compositions, et régimes de dosage dans le traitement des infections par le sars-cov-2
US20230285434A1 (en) * 2020-04-14 2023-09-14 Oyagen, Inc. Method for treating arenaviridae infections
CA3098164A1 (fr) * 2020-11-05 2022-05-05 Eurofins Cdmo Alphora Inc. Procede de preparation d'un intermediaire avance pour la synthese d'eribuline
AU2022331233A1 (en) 2021-08-20 2024-02-29 Shionogi & Co., Ltd. Nucleoside derivatives and prodrugs thereof having viral growth inhibitory action
CN113666941B (zh) * 2021-09-01 2023-03-10 浙江珲达生物科技有限公司 一种2,3-O-异亚丙基-D-核糖酸-γ-内酯的重结晶方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985848A (en) * 1997-10-14 1999-11-16 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
WO2000061783A2 (fr) * 1999-04-08 2000-10-19 Industrial Research Limited Procede permettant de preparer des inhibiteurs du metabolisme des nucleosides
MY141594A (en) * 2000-06-15 2010-05-14 Novirio Pharmaceuticals Ltd 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
WO2002018371A1 (fr) * 2000-08-29 2002-03-07 Industrial Research Limited Inhibiteurs du metabolisme des nucleosides
WO2002069903A2 (fr) 2001-03-06 2002-09-12 Biocryst Pharmaceuticals, Inc. Nucleosides, leur preparation et utilisation en tant qu'inhibiteurs de polymerases virales d'arn
US7388002B2 (en) 2001-11-14 2008-06-17 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
US7098334B2 (en) * 2002-03-25 2006-08-29 Industrial Research Limited 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
US20040242599A1 (en) 2003-02-27 2004-12-02 Biocryst Pharmaceuticals, Inc. Cyclopentene nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
US20050187170A1 (en) 2003-06-16 2005-08-25 Biocryst Pharmaceuticals, Inc. Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors
US20050080053A1 (en) 2003-08-29 2005-04-14 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
GEP20084545B (en) * 2003-09-05 2008-11-25 Anadys Pharmaceuticals Inc Introducing tlr7 ligands and prodrugs thereof for the treatment of hepatitis c viral infection
US20070167353A1 (en) * 2003-10-24 2007-07-19 John Hilfinger Prodrug composition
WO2006002231A1 (fr) * 2004-06-22 2006-01-05 Biocryst Pharmaceuticals, Inc. Azanucleosides, leur preparation et leur utilisation comme inhibiteur des arn polymerases virales
KR20070100237A (ko) 2004-10-29 2007-10-10 바이오크리스트 파마수티컬즈, 인코퍼레이티드 치료용 푸로피리미딘 및 티에노피리미딘
BRPI0607769A2 (pt) * 2005-02-28 2009-10-06 Genelabs Tech Inc pró-fármacos nucleosìdeo-tricìclicos para tratamento de infecções virais
AU2006230023A1 (en) * 2005-03-29 2006-10-05 Biocryst Pharmaceuticals, Inc. Hepatitis C therapies
AU2006280175B2 (en) * 2005-08-09 2011-09-01 Merck Sharp & Dohme Corp. Ribonucleoside cyclic acetal derivatives for the treatment of RNA-dependent RNA viral infection
WO2007069924A1 (fr) * 2005-12-15 2007-06-21 Industrial Research Limited Analogues de déazapurine de 4'-aza-l-nucléosides
US7759495B2 (en) * 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR20090094800A (ko) 2006-09-11 2009-09-08 써던 리서취 인스티튜트 아졸 뉴클레오시드 및 알엔에이와 디엔에이 바이러스성 폴리머라제 억제제로의 이용
SG177974A1 (en) 2007-01-12 2012-02-28 Biocryst Pharm Inc Antiviral nucleoside analogs
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
CA2755950C (fr) * 2009-03-24 2017-04-25 Biocryst Pharmaceuticals, Inc. Sels pharmaceutiques utiles de 7-[(3r,4r)-3-hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-one
JP5902698B2 (ja) * 2010-10-15 2016-04-13 バイオクライスト ファーマシューティカルズ， インコーポレイテッド ポリメラーゼの阻害のための方法および組成物

Also Published As

Publication number Publication date
TWI664180B (zh) 2019-07-01
KR102409853B1 (ko) 2022-06-15
TW201345912A (zh) 2013-11-16
US20150191472A1 (en) 2015-07-09
IL235123A (en) 2017-09-28
EP2838535B1 (fr) 2019-03-06
CN104379146B (zh) 2018-07-10
JP6559266B2 (ja) 2019-08-14
MX363270B (es) 2019-03-19
KR20210011517A (ko) 2021-02-01
US9580428B2 (en) 2017-02-28
KR20150002844A (ko) 2015-01-07
KR20200070428A (ko) 2020-06-17
AR090699A1 (es) 2014-12-03
BR112014025909B1 (pt) 2021-09-14
RU2654482C2 (ru) 2018-05-21
AU2013249344B2 (en) 2018-06-07
CN104379146A (zh) 2015-02-25
JP2015514772A (ja) 2015-05-21
CA2870722C (fr) 2020-05-12
BR112014025909A2 (fr) 2017-06-20
RU2014145857A (ru) 2016-06-10
AU2013249344A1 (en) 2014-11-27
JP2018111692A (ja) 2018-07-19
EP2838535A4 (fr) 2015-09-09
WO2013158746A1 (fr) 2013-10-24
EP2838535A1 (fr) 2015-02-25
CA2870722A1 (fr) 2013-10-24
KR102156819B1 (ko) 2020-09-16
US20170128454A1 (en) 2017-05-11
MX2014012525A (es) 2015-01-15

Similar Documents

Publication Publication Date Title
HUS2200034I1 (hu) Glikokonjugációs eljárások és kompozíciók
HK1211058A1 (en) Highly multiplex pcr methods and compositions pcr
GB2518764B (en) Methods and compositions for RNA-directed target DNA modification
LT2742151T (lt) Polimerazės kompozicija
PL3260558T3 (pl) Nowe kompozycje i sposoby poprawy specyficzności pcr
EP2836212A4 (fr) Nouvelles compositions et nouveaux procédés
ZA201408594B (en) Xylitol-based anti-mucosal compositions and related methods and compositions
HK1206627A1 (en) Compositions and methods for inhibiting viral polymerase
PL2911506T3 (pl) Kompozycje zmniejszające dryf
HK1217117A1 (zh) 用於使 試劑穩定化的製劑和方法
HK1216250A1 (zh) '- '-羥基-二氫麥角胺化合物及組合物
ZA201503458B (en) Hepatitis c virus inhibitors
EP2869821A4 (fr) Compositions et méthodes de traitement et d'inhibition d'infections virales
EP2802353A4 (fr) Compositions et méthodes de traitement d'infections virales
EP2902488A4 (fr) Adn polymérase modifiée
EP2912060A4 (fr) Compositions et procédés pour inhiber une infection pathogène
GB2502554B (en) Primers
GB201315350D0 (en) Methods and compositions
GB201315347D0 (en) Methods and compositions
EP2931280A4 (fr) Procédés et compositions pour l'inhibition de cnksr1
EP2931746A4 (fr) Procédés et compositions pour l'inhibition spécifique de ckap5 par un arn à double brin
ZA201303410B (en) Viral polymerase inhibitors
EP2852662A4 (fr) Compositions de virus herpétique et procédés associés
EP2981334A4 (fr) Compositions et procédés d'inhibition de l'activité virale
PT2838903T (pt) Métodos e composições para tratamento de infeções virais